Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic
dermatologic side effects. Cetuximab, erlotinib, and gefitinib have been approved for …

The growing investigation and use of epidermal growth factor receptor (EGFR) inhibitors in
anticancer therapy has been motivated by their specificity for EGFR, which improves their …

The last few years, new therapies targeting the epidermal growth factor receptor (EGFR)
have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies …

The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors
has increased considerably in recent years. Currently, they are approved in non-small cell …

Background Acute and subacute cutaneous side‐effects of epidermal growth factor receptor
inhibitors (EGFRIs) are very frequent and well known. Much less is known about the chronic …

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid
tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the …

The human epidermal growth factor receptor (HER1/EGFR) is dysregulated in many solid
tumors, making it an attractive target for anticancer therapy. A number of agents that target …

Epidermal growth factor receptor inhibitors (EGFRIs) have demonstrated improved overall
survival in patients with non-small cell lung cancer, pancreatic cancer, and colorectal …

The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of solid
tumours is increasing. However, the tolerability profile for EGFR‐inhibitors, such as the …

Biologic agents targeting the epidermal growth factor receptor (EGFR) have emerged as a
robust treatment option for various solid tumors. Despite lower systemic side effects than …